Immunotherapy (Investigational)

19 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Investigational) (19)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
BMS-986156 (GITR)	Costimulatory / Bispecific Agent	Solid Tumour
Molecule BMS-986156 (GITR) Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Cibisatamab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Cibisatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Etentamig	Bispecific T-Cell Engager, BCMA x CD3	Hematologic (Multiple Myeloma)
Molecule Etentamig Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, BCMA x CD3
Evorpacept	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Evorpacept Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Forimtamig	Bispecific T-Cell Engager, GPRC5D x CD3	Hematologic (Multiple Myeloma)
Molecule Forimtamig Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, GPRC5D x CD3
IBI322 (CD47/PD-L1)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule IBI322 (CD47/PD-L1) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
INCAGN1876 (GITR)	Costimulatory / Bispecific Agent	Solid Tumour
Molecule INCAGN1876 (GITR) Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Ivonescimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Lemzoparlimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Lemzoparlimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Letaplimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Magrolimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Magrolimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
MEDI1873 (GITR)	Costimulatory / Bispecific Agent	Solid Tumour
Molecule MEDI1873 (GITR) Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

BMS-986156 (GITR) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Cibisatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Etentamig Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, BCMA x CD3
Evorpacept Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Forimtamig Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Bispecific T-Cell Engager, GPRC5D x CD3
IBI322 (CD47/PD-L1) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
INCAGN1876 (GITR) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Lemzoparlimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Magrolimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
MEDI1873 (GITR) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

‹ 1 2 ›

Product Range

Company

Global Network

Immunotherapy (Investigational)

Immunotherapy (Investigational) (19)

BMS-986156 (GITR)

Cibisatamab

Etentamig

Evorpacept

Forimtamig

IBI322 (CD47/PD-L1)

INCAGN1876 (GITR)

Ivonescimab

Lemzoparlimab

Letaplimab

Magrolimab

MEDI1873 (GITR)

BMS-986156 (GITR)

Cibisatamab

Etentamig

Evorpacept

Forimtamig

IBI322 (CD47/PD-L1)

INCAGN1876 (GITR)

Ivonescimab

Lemzoparlimab

Letaplimab

Magrolimab

MEDI1873 (GITR)